Pfizer and BioNTech recently reported top-line results from a trial of its combination vaccine that was meant to protect against the flu and COVID-19. The partners' combination shot failed to achieve ...

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

The CHMP’s recommendation will be reviewed by the European Commission (EC), which is expected to make its final decision soon. Pfizer and BioNTech have already initiated manufacturing of the ...

Germany's BioNTech and US pharma giant Pfizer said Friday they had suffered a setback in a late-stage trial of their combined mRNA vaccine against COVID-19 and influenza. In a phase 3 trial, the combo ...

LONDON, July 10 (Reuters) - Pfizer and its German partner BioNTech asked London's Court of Appeal on Thursday to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents, in ...

A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine. Siding with Moderna, an American pharmaceutical firm ...

BioNTech (BNTX) has reached settlement agreements with the U.S. National Institutes of Health (NIH) and the University of Pennsylvania over royalties tied to its COVID-19 vaccine, resolving disputes ...

Thursday, the FDA granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component that corresponds to the Omicron variant KP ...